Cryo-Cell (CCEL) CIO granted new performance-based stock options
Rhea-AI Filing Summary
Cryo-Cell International's Chief Information Officer, Oleg Mikulinsky, reported new equity awards and existing holdings. On January 7, 2026, he received two grants of stock options on the company’s common stock at an exercise price of $3.54 per share, one for 10,000 options that vest in thirds on January 7, 2026, 2027 and 2028, and another for 20,000 options granted under the Cryo-Cell 2022 Stock Incentive Plan with three tranches tied to both time and stock-price performance hurdles at $6, $8, and $10 per share over specified 20-day periods. He also reports direct ownership of 104,349 common shares and several prior option awards with varying exercise prices and vesting schedules.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 10,000 | $3.54 | $35K |
| Grant/Award | Stock Option | 20,000 | $3.54 | $71K |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Stock options vest 1/5 per year commencing on September 23, 2021. Stock options vest immediately if the price of the Company's stock reaches $25.00 per share during the seven year option period. Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025. Stock options vest 1/3 upon issuance, 1/3 on January 22, 2026 and 1/3 on January 22, 2027. Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028. The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least $6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least $8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least $10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company.
FAQ
What insider activity did Cryo-Cell (CCEL) report for Oleg Mikulinsky?
The filing shows that Chief Information Officer Oleg Mikulinsky reported new stock option grants on January 7, 2026, along with his existing common stock and option holdings.
How many new stock options did the Cryo-Cell CIO receive on January 7, 2026?
He received two new stock option grants: one for 10,000 options and another for 20,000 options, each with an exercise price of $3.54 per share.
What are the vesting terms for the 10,000 Cryo-Cell options granted at $3.54?
The 10,000 options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028, subject to continued service.
What performance conditions apply to the 20,000 Cryo-Cell options granted at $3.54?
The 20,000 options are split into three equal tranches that each require both time-based vesting and the stock achieving an average closing price of at least $6, $8, or $10 per share over 20 consecutive trading days, in addition to continued service.
What existing Cryo-Cell stock option awards does the CIO hold besides the new grants?
He holds several earlier stock option awards on common stock with exercise prices including $7.49, $7.13, $6.55, $8, $11.90, $5.88, and $7.35, each with its own vesting schedule and expiration date.